Author Archive

New CMS Guidance for Biotech Industry On Coverage With Evidence Development: It’s All About The Outcomes

This is a guest post from Robert E. Wanerman, a member of Epstein Becker Green’s Health Care and Life Sciences practice. Do you have a response to Robert’s post? Respond in the comments section below. For many biotech manufacturers, obtaining Medicare coverage is a significant milestone in commercializing an item or service. Although Medicare coverage […]

New Years Bio-Pharmaceutical Resolution To Nurture MSME Innovation

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. At the start of a bright and shiny new year in 2015, I am thinking about my own New Years resolutions as well as one that I would […] posts public-domain inventions

Patents require regular ‘maintenance’ payments to keep them in force. Because the cost of maintaining large patent portfolios can be substantial, many companies elect to abandon patents that they feel are not worth pursuing. Sometimes these patents are abandoned because they are outside a company’s focus, and in other cases they may represent markets too small for […]

Unlocking the Mystery of Angel Investment

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In the “Mystery of Capital,” Peruvian economist Hernando de Soto famously writes about the need to convert assets into capital for creation of social and economic value in […]

More on The Success Matrix

Gerry Langeler, author of The Success Matrix and Managing Director with OVP Venture Partners recently spoke at a breakfast event and was kind enough to record the video. Gerry’s thoughts on ‘Why scientists fail as entrepreneurs‘ was previously featured on the BiotechBlog, and his video is posted below. For more, you can also visit Gerry’s website at  

Key Elements of Succession Planning In Bioscience

This is a guest post from Steve McLaughlin, Managing Partner and Founder of US BioSearch. Do you have a response to Steve’s post? Respond in the comments section below. Effective succession plans involve a combination of many choices and decisions that are distinctive to each, specific company. Bioscience companies also present their own, unique challenges, as […]

Building Biotechnology in Poland

I will be presenting at Bioinnovation 2014 in Gdansk, Poland on October 20-21st. My talk will cover entrepreneurship and business development guidance from my textbook, Building Biotechnology and global competitiveness considerations from my global biotechnology ranking for Scientific American Worldview. I look forward to meeting European and Polish biotechnology practitioners, and learning more about biotechnology […]

Maintaining your independence in biotechnology

Mergers and acquisitions are regular events for biotechnology companies. I have often been asked if being acquired is a goal for biotechnology companies, and if it is seen as a ‘good’ or a ‘bad’ thing. The outlook on merging with another company, or being acquired, is really just a matter of timing. As I describe […]

Adventures in Data Wrangling

I will be giving a talk on September 10th at George Washington University on two recent data analytics projects: Firstly, I will present Scientific American Worldview, a global biotechnology ranking I developed six years ago and have managed since. The primary challenges in developing Worldview have been ensuring that the product is accessible to a […]